Arginine malate

Other Names

(2R)-2-Hydroxysuccinic acid - arginine (1:1)(2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid and 2-hydroxybutanedioic acid(2S)-2-Amino-5-carbamimidamidopentanoic acid; 2-hydroxybutanedioic acid(S)-2-Amino-5-guanidinopentanoic acid 2-hydroxysuccinic acid (1:1)Acide 2-hydroxysuccinique - arginine (1:2)Arginin--2-hydroxybernsteinsäure (2:1)Arginine - 2-hydroxysuccinic acid (2:1)Arginine, compd. with 2-hydroxybutanedioic acid (2:1)Diarginine malateL-Arginin--2-hydroxybernsteinsäure (1:1)L-Arginine - 2-hydroxysuccinic acid (1:1)L-Arginine - acide 2-hydroxysuccinique (1:1)L-Arginine L-malateL-Arginine malateL-Arginine, compd. with 2-hydroxybutanedioic acid (1:1)

Synopsis

Arginine Malate

1. Identity and Chemical Characterization

Chemical Names and Structure

Arginine malate has the molecular formula C₁₀H₂₀N₄O₇ and is registered in PubChem under Compound Identifier (CID) 76962777. The compound is formally a salt formed by combining the amino acid L-arginine with malic acid. The CAS registry number for the L-arginine malate salt form is 41989-03-1. As a salt, arginine malate dissociates in aqueous solution to yield its two constituent ions, meaning that physiological actions may be attributed both to the arginine portion and to the malate (malic acid) portion individually, as well as to potential synergistic interactions between the two moieties.

Arginine itself is the amino acid with the formula (H₂N)(HN)CN(H)(CH₂)₃CH(NH₂)CO₂H. The molecule features a guanidino group appended to a standard amino acid framework. At physiological pH, the carboxylic acid is deprotonated and both the amino and guanidino groups are protonated, resulting in a cation. Only the L-arginine enantiomer is found naturally.

Arginine, also known as L-arginine (symbol Arg or R), is an α-amino acid that is mainly used for the biosynthesis of proteins. It contains an α-amino group, an α-carboxylic acid group, and a side chain consisting of a 3-carbon aliphatic straight chain ending in a guanidino group, which results in arginine being a charged aliphatic amino acid at physiological pH.

Malic acid is a naturally occurring dicarboxylic acid that plays a central role in cellular metabolism, particularly as an intermediate in the citric acid (Krebs) cycle, where it facilitates the conversion of malate to oxaloacetate, contributing to energy production in cells. Its mechanism of action involves its participation as a substrate for malic enzyme, which catalyzes the oxidative decarboxylation of malate to pyruvate, generating NAD(P)H in the process; this reaction is crucial for cellular redox balance and biosynthetic pathways.

Common Forms and Related Preparations

Arginine malate belongs to a broader family of arginine salt forms used in dietary supplementation. Supplements of arginine, ornithine, or citrulline are commonly ingested as the chloride salt or as the salt of other anions such as α-ketoglutarate (i.e., ornithine α-ketoglutarate, or OKG), aspartate, pyroglutamate, or malate. The organic anion may exert synergistic effects, as appears to be the case with OKG. Related and commonly confused products include arginine alpha-ketoglutarate (AAKG), arginine aspartate, and citrulline malate (in which the amino acid is L-citrulline rather than L-arginine). Citrulline malate, for example, is a mixture of citrulline and malic acid in ratios ranging from 1:1 to 2:1. Arginine malate is sold commercially as powders intended for dissolution in water (drink mixes), as well as in capsule and tablet form.

2. Natural Sources of the Constituent Compounds

L-Arginine in Food and Endogenous Synthesis

Arginine is classified as a semiessential or conditionally essential amino acid, depending on the developmental stage and health status of the individual. Most healthy people do not need to supplement with arginine because it is a component of all protein-containing foods and can be synthesized in the body from glutamine via citrulline.

Internally, around 80% of arginine in the body is produced through protein turnover and 15% is synthesized from citrulline in the urea cycle. Most de novo synthesis happens via the intestinal-renal axis: citrulline is produced by epithelial cells in the small intestine, mainly from ornithine, glutamine, and glutamate.

Arginine is available in meat, nuts, wheat germ, and dairy products. The maximum intake of arginine with a typical diet is approximately 5 g/day. Good dietary protein sources of arginine include meat, poultry, dairy products, soybeans, chickpeas, spirulina, nuts, and seeds.

Preterm infants are unable to synthesize arginine internally, making the amino acid nutritionally essential for them. Additional dietary arginine is necessary for otherwise healthy individuals temporarily under physiological stress, for example during recovery from burns, injury, or sepsis, or if either of the major sites of arginine biosynthesis, the small intestine and kidneys, have reduced function.

Malic Acid in Food

Malic acid is a naturally occurring substance that is produced by the body during the conversion of carbohydrates into energy. It is found abundantly in tart fruits, particularly apples (from which it takes its name, derived from the Latin malum, meaning apple), cherries, grapes, and other fruits. Malic acid contributes to the characteristic tartness of many fruits and is widely used as a food acidulant (E296 in the European Union food additive system).

3. Historical and Traditional Use

L-Arginine: Discovery and Early Research

Arginine's story begins in 1886, when it was first isolated from lupin seeds by Schulze and Steiger. In its crystallized form, it has a silvery appearance, which inspired Schulze to name it after the Greek word for silver, árgyros. Arginine is an amino acid involved in many different metabolic processes, including protein synthesis and the synthesis of nitric oxide, urea, creatine, and other metabolites.

Arginine and ornithine were first used clinically to treat hyperammonemia by providing a sufficient supply of urea cycle intermediates. This was a serendipitous finding that arose from the switch from protein hydrolysates for intravenous nutrition to L-amino acid mixtures in the mid-1980s. These early clinical applications established arginine as a physiologically significant molecule for nitrogen metabolism before its role in nitric oxide synthesis became apparent.

The discovery that L-arginine is the biological precursor to nitric oxide — announced in a landmark series of studies in the late 1980s and recognized by the 1998 Nobel Prize in Physiology or Medicine awarded to Furchgott, Ignarro, and Murad — transformed the perception of this amino acid and prompted extensive investigation into its supplemental use for cardiovascular and other applications. This scientific development, rather than any traditional ethnobotanical practice, forms the primary historical context for L-arginine supplementation.

Arginine Malate as a Salt Form: Context of Use

The specific salt form of arginine malate does not have a distinct record of traditional or ethnobotanical use in any single culture or historical period. Rather, it represents a pharmaceutical and nutraceutical development of the late twentieth century in which malic acid (an established metabolic intermediate) was combined with L-arginine to create a salt with potentially improved stability, palatability, and dual metabolic activity. Malic acid has been marketed as a therapeutic supplement, particularly for conditions such as fibromyalgia, where individuals may have difficulty utilizing malic acid effectively. The coupling of arginine with malate reflects a strategy of combining known biochemical intermediates into a single formulation.

Traditional Use of Malic Acid

Malic acid has been explored for therapeutic uses including the treatment of dry mouth, where it has shown positive results in double-blind, placebo-controlled trials. Despite its widespread availability in combination products aimed at alleviating fibromyalgia symptoms, there is limited scientific evidence to support its efficacy in that context specifically.

4. Key Constituents and Mechanisms of Action

L-Arginine: Nitric Oxide Synthesis

L-arginine is a conditionally essential amino acid that functions as a substrate for nitric oxide synthase (NOS) and participates in the urea cycle, thereby influencing vascular tone, ammonia detoxification, and metabolic regulation. L-arginine is the main precursor of nitric oxide (NO) via nitric oxide synthase (NOS) activity.

NO plays an important role in many functions in the body, regulating vasodilation, blood flow, mitochondrial respiration, and platelet function. Nitric oxide is known to have blood-flow-enhancing effects, which could in theory increase the delivery of oxygen and nutrients to exercising muscle.

In mammals, arginine is also responsible for the production of nitric oxide (NO), creatine, and polyamines (putrescine, spermidine, and spermine), which have been shown to act as vital regulators for the synthesis of DNA and proteins, scavenging of reactive oxygen species (ROS), inhibition of autophagy, cell proliferation, and fat metabolism.

Current interest in L-arginine is focused mainly on its role in biosynthesis of nitric oxide and its stimulatory role in the secretion of insulin and growth hormone.

L-Arginine: Urea Cycle and Ammonia Metabolism

L-arginine is a conditionally essential amino acid that plays a number of important roles in body functions including protein synthesis and detoxification of ammonia formed during the nitrogen catabolism of amino acids via the formation of urea. Arginine facilitates the removal of ammonia, helps to maintain the immune system during sepsis, and can function to enhance healing in trauma or burn patients.

L-Arginine: Additional Biosynthetic Roles

L-arginine is required for the formation of creatine and other critical compounds for body function, such as nitric oxide, polyamines, L-glutamate, L-proline, agmatine (a possible neurotransmitter in the brain), and the L-arginine-containing tetrapeptide tuftsin.

Previous studies have suggested that L-arginine supplementation may improve endurance performance, enhance oxygen delivery, and modulate immune and antioxidant responses. L-arginine has been reported to increase glycogen storage, regulate lactate metabolism, and attenuate markers of muscle injury.

Malate (Malic Acid): Krebs Cycle Intermediary and Energy Metabolism

Malic acid is a naturally occurring dicarboxylic acid that plays a central role in cellular metabolism, particularly as an intermediate in the citric acid (Krebs) cycle, where it facilitates the conversion of malate to oxaloacetate, contributing to energy production in cells. When arginine malate dissociates, the liberated malate ion can enter directly into the Krebs cycle, potentially replenishing cycle intermediates (an "anaplerotic" effect) and sustaining aerobic ATP production.

The malate portion contributes to cellular energy production via the Krebs cycle, which may support the metabolic processing of ammonia, a byproduct of the urea cycle.

Potential Synergy Between Arginine and Malate

The rationale for combining L-arginine with malate is that both compounds address partially overlapping physiological pathways. L-arginine supports NO-mediated vasodilation and ammonia clearance, while malate supports aerobic energy metabolism. The organic anion (such as malate) may exert synergistic effects with arginine, as appears to be the case with ornithine alpha-ketoglutarate (OKG), where the organic anion combination has been observed to have distinct properties relative to either compound alone. The specific magnitude and nature of synergy between arginine and malate in humans has not been definitively established in controlled clinical trials that isolate arginine malate as a compound from the actions of its individual constituents.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health and Blood Pressure

The most extensively researched application of L-arginine supplementation is its effect on blood pressure and vascular function, via NO-mediated vasodilation. The evidence base is primarily for L-arginine itself, which is the pharmacologically active moiety delivered by arginine malate.

L-arginine, an amino acid and a substrate of nitric oxide synthase, may have a blood pressure-lowering effect. Because some studies were performed with a limited number of patients with hypertension and therefore limited statistical power with sometimes inconsistent results, a meta-analysis of randomized, double-blind, placebo-controlled trials was conducted. This meta-analysis provided further evidence that oral L-arginine supplementation significantly lowers both systolic and diastolic blood pressure.

A subsequent and more comprehensive systematic review and dose-response meta-analysis of randomized clinical trials confirmed these findings. In a nonlinear dose-response analysis, the effective dosage of L-arginine supplementation was detected to be ≥4 g/day for systolic blood pressure reduction (p = 0.034), independent of trial duration. Overall, L-arginine supplementation may be effective for decreasing blood pressure.

In one double-blind randomized controlled trial conducted in 56 participants at Isfahan University of Medical Sciences, healthy men received L-arginine supplementation (2,000 mg daily) or placebo for 45 days. At the end of the study, fasting blood sugar and lipid profile (triglycerides, cholesterol, LDL, HDL) were significantly decreased in the L-arginine group but not in the placebo group, and these reductions in the L-arginine group were significant compared with placebo.

In a randomized, double-blind, placebo-controlled trial, 118 adults with elevated blood pressure were recruited and randomly assigned to either a placebo group or an intervention group receiving 9 g/day of L-arginine supplementation for 2 weeks. On the 14th day, participants walked along a traffic road for 2 hours; resting blood pressure, L-arginine–nitric oxide metabolites, and inflammatory biomarkers were measured. Participants in the intervention group had significantly elevated plasma L-arginine levels compared to the placebo group after supplementation.

Evidence strength: The blood-pressure-lowering effect of oral L-arginine is supported by multiple RCTs and meta-analyses, but effect sizes vary across populations and are generally modest. Most studies have investigated L-arginine as a free base or in salt forms other than the specific malate combination; clinical data for arginine malate specifically as a distinct formulation are sparse.

5.2 Athletic Performance and Exercise Physiology

The use of L-arginine, L-citrulline, and citrulline malate supplements has been shown to enhance cardiovascular health and athletic performance. Over the past decade, these supplements have received considerable attention from researchers in the field of exercise nutrition, who have investigated their potential effects on hemodynamic function, endothelial function, aerobic and anaerobic capacity, strength, power, and endurance.

A 2023 narrative review systematically examined the published evidence: the results showed that both recreational and trained athletes did not see improved physical performance or increased nitric oxide (NO) synthesis with 0.075 g or 6 g doses of L-arginine supplement per body weight. The effects of an 8 g acute dose of citrulline malate supplement were inconsistent, and more research is needed to determine its impact on muscle endurance performance.

Regarding the related compound arginine alpha-ketoglutarate (AAKG), which is another arginine-organic acid salt, clinical data are informative. A study examined the efficacy of acute ingestion of L-arginine alpha-ketoglutarate (AAKG) on muscular strength and endurance in resistance-trained and untrained men. Eight resistance-trained and eight untrained healthy males ingested either 3,000 mg of AAKG or a placebo 45 minutes prior to a resistance exercise protocol in a randomized, double-blind crossover design. The results indicated that acute AAKG supplementation provides no ergogenic benefit on 1-repetition maximum (1RM) or total lifting volume as measured by the standard barbell bench press and leg press.

A longer-duration AAKG study involved weight-training men. In a placebo-controlled study, 35 resistance-trained adult men (30–50 years old) were randomly assigned to ingest 4 g of AAKG three times a day (12 g daily) or placebo, and participants performed 4 days of periodized resistance training per week for 8 weeks.

A 2025 randomized, double-blind, placebo-controlled trial examined the effects of combined L-arginine and citrulline malate supplementation specifically. This study investigated the effects of combined L-arginine and citrulline-malate supplementation on aerobic, anaerobic, and high-intensity interval training in healthy, trained men. Both L-arginine and citrulline malate are widely marketed for their potential ergogenic effects, as L-arginine serves as a precursor to nitric oxide, which may support vasodilation, muscle contractility, and exercise performance. The two compounds are hypothesized to exert synergistic effects due to their complementary roles in NO synthesis. Citrulline can potentially enhance and prolong L-arginine availability, thereby amplifying NO-mediated vasodilation, nutrient delivery, and muscle performance during exercise.

The training status of subjects appears to be an important modifying variable. The ergogenic response of L-citrulline or L-arginine supplements depends on the training status of the subjects. Studies involving untrained or moderately healthy subjects showed that NO donors could improve tolerance to aerobic and anaerobic exercise. However, when highly trained subjects were supplemented, no positive effect on performance was indicated.

Evidence strength: The evidence for L-arginine alone as an ergogenic aid is weak and largely inconsistent across studies. Mixed or modestly positive findings are more common when L-arginine is combined with other NO-pathway agents or when subjects are untrained. There are no published RCTs that have specifically tested arginine malate (the discrete salt) as an ergogenic formulation independent of other compounds.

5.3 Fatigue and Exercise Recovery

L-arginine is a conditionally essential amino acid that serves as a substrate for nitric oxide synthase and regulates energy metabolism. While its ergogenic effects have been proposed, the mechanisms underlying its anti-fatigue properties are not fully understood.

A prospective clinical study examined arginine malate specifically in patients recovering from COVID-19 infection. This study involved SARS-CoV-2-infected patients divided into two groups: Group 1 received a product containing arginine aspartate, vitamin B6, biotin, and magnesium; Group 2 received a product containing L-arginine and malic acid. The patients visited family physicians from October 2021 to January 2022, complaining of physical and/or mental fatigue following the COVID-19 infection. 505 patients were recorded and the fatigue level was analyzed using the Fatigue Assessment Scale (FAS) through its total, mental, and physical scores, at baseline and after three months of treatment.

Nutritional supplementation with L-arginine and L-aspartate leads to an increase in fat oxidation and reduces blood lactate and associated oxygen consumption and heart rate and ventilation during submaximal cycle exercise. This may involve exercise tolerance, which may have important implications for patients diagnosed with COVID-19.

In a separate randomized controlled trial of patients with long COVID, L-arginine was combined with vitamin C rather than malate. A single-blind randomized, placebo-controlled trial was conducted in adults aged between 20 and 60 years with persistent fatigue attending a post-acute COVID-19 outpatient clinic. Participants were randomized 1:1 to receive twice-daily orally either a combination of 1.66 g L-arginine plus 500 mg liposomal vitamin C or a placebo for 28 days. At 28 days, L-arginine plus vitamin C increased the 6-minute walk distance (+30 m) compared to placebo and induced a greater improvement in handgrip strength; the flow-mediated dilation was greater in the active group than in the placebo group (14.3% vs. 9.4%); and fatigue was reported by only two participants (8.7%) in the active group compared to 21 (80.1%) in the placebo group (p < 0.0001).

The anti-fatigue properties of malic acid in the context of fibromyalgia have a separate investigative history. Extremely preliminary evidence suggests that individuals with fibromyalgia might have difficulty creating or utilizing malic acid, and such a deficiency could interfere with normal muscle function. In an early randomized, double-blind, placebo-controlled, crossover pilot study in 24 patients with fibromyalgia, malic acid 200 mg plus magnesium 50 mg was used; with dose escalation and a longer duration of treatment in an open-label trial, significant reductions in the severity of all three primary pain/tenderness measures were obtained. Despite widespread availability of combination products aimed at alleviating fibromyalgia symptoms, there is limited scientific evidence to support their efficacy.

Evidence strength: Evidence for arginine malate specifically in fatigue is preliminary and is largely based on observational or single open-label/uncontrolled studies. Stronger evidence exists for L-arginine in combination with vitamin C for post-COVID fatigue and physical deconditioning. The malic acid-fibromyalgia literature is based on a small, early pilot trial and remains inconclusive.

5.4 Erectile Dysfunction and Sexual Function

Nitric oxide (NO) is a critical signaling molecule that relaxes smooth muscle in the penile arteries and corpus cavernosum, allowing increased blood flow and erection. L-arginine is converted by nitric oxide synthase into NO.

L-arginine has been studied alone as well as in combination with various other molecules for the treatment of erectile dysfunction, but the studies are very limited in number and have very small sample sizes. Positive evidence is available for the efficacy of L-arginine and its various combinations.

A multicentre, double-blind, randomized, placebo-controlled clinical trial investigated high-dose oral L-arginine supplementation for vasculogenic erectile dysfunction. The trial addressed the effects on penile erectile function of relatively high daily oral doses (6 g/day) of L-arginine for 3 months (n = 51) compared to placebo (n = 47), in patients with vasculogenic erectile dysfunction, with comparison between mild–moderate and severe vasculogenic ED. The outcome measures included IIEF-6 score and cavernous arteries peak systolic flow velocity (PSV) at dynamic penile duplex ultrasonography. L-arginine supplementation for 3 months significantly increased IIEF-6 score in the overall cohort (p < 0.0001) and in subgroups of patients with mild–moderate (p < 0.0001) and severe (p = 0.007) vasculogenic ED; PSV was significantly increased in the overall cohort (p < 0.0001) and in patients with mild–moderate (p < 0.0001), but not severe vasculogenic ED.

Evidence strength: The evidence for L-arginine in vasculogenic erectile dysfunction is moderately positive, particularly for mild-to-moderate cases. The above RCT used L-arginine free base at 6 g/day, not specifically the malate salt. Larger and longer trials are needed before firm clinical recommendations can be made.

5.5 Growth Hormone Secretion

Current interest in L-arginine includes its stimulatory role in the secretion of growth hormone. A systematic review and meta-analysis specifically examined this area. This study aimed to review the effects of L-arginine supplementation alone and combined with growth hormone-releasing hormone (GHRH) on GH secretion; eligible studies were randomized clinical trials that reported the effects of arginine supplementation alone or with GHRH on GH levels. Meta-analyses showed significant effects of arginine alone on GH release (mean difference = 10.07, 95% CI: 7.87, 12.28). Moreover, the GH response was greater with arginine combined with GHRH (mean difference = 24.96, 95% CI: 17.51, 32.42). There was no significant difference between patients and healthy individuals, and between oral and injection use of arginine.

Evidence strength: Intravenous and, to a lesser extent, oral L-arginine has an established pharmacodynamic effect on growth hormone release. The clinical significance of this effect for healthy individuals taking oral arginine supplementation is less certain, and it is primarily used diagnostically in clinical endocrinology rather than therapeutically.

5.6 Endothelial Function

Supplementation of L-arginine may improve endothelial and muscle function by stimulating nitric oxide synthesis. Researchers have investigated the potential effects of arginine and citrulline supplements on hemodynamic function and endothelial function. Endothelial function, commonly assessed via flow-mediated dilation (FMD) of the brachial artery, has been reported to improve in clinical studies of L-arginine supplementation in populations with cardiovascular risk factors or established cardiovascular disease. However, as with blood pressure findings, available clinical data pertain to L-arginine as a free base or in various salt forms, not specifically to the arginine malate salt.

6. Body Systems and Health Areas of Association

Cardiovascular system: The use of L-arginine supplements has been shown to enhance cardiovascular health through NO-mediated vasodilation, blood pressure reduction, and improvements in endothelial function.
Skeletal muscle and exercise physiology: L-arginine functions as a substrate for nitric oxide synthase and participates in metabolic regulation; previous studies have suggested it may improve endurance performance, enhance oxygen delivery, and modulate immune and antioxidant responses.
Urea cycle and nitrogen metabolism: L-arginine participates in the urea cycle, thereby influencing ammonia detoxification.
Cellular energy metabolism: The malate component acts as an intermediate in the citric acid (Krebs) cycle, facilitating the conversion of malate to oxaloacetate and contributing to cellular energy production.
Endocrine system: L-arginine has a stimulatory role in the secretion of insulin and growth hormone.
Immune and wound healing: Arginine is involved in cell division, hormone release, wound healing, and T-cell function.
Sexual function: Via NO-mediated relaxation of cavernosal smooth muscle, arginine is mechanistically linked to erectile physiology.
Fibromyalgia and chronic fatigue (preliminary): Malic acid has been marketed as a supplement, particularly for fibromyalgia, where individuals may have difficulty utilizing malic acid effectively.

7. Dosage Forms and Reported Study Dosages

Arginine malate is commercially available in powder, capsule, and tablet forms. The following dosages are reported directly from the cited research studies and should not be interpreted as prescriptive recommendations.

In a randomized, double-blind crossover study of acute AAKG supplementation (a related arginine-organic acid salt), 3,000 mg was ingested 45 minutes prior to a resistance exercise protocol.
In an 8-week AAKG study, 35 resistance-trained adult men were randomly assigned to ingest 4 g of AAKG three times a day (12 g daily) or placebo.
In the vasculogenic erectile dysfunction trial, 6 g/day of L-arginine was administered for 3 months.
In the long COVID fatigue trial, participants received twice-daily oral doses of 1.66 g L-arginine (combined with 500 mg liposomal vitamin C) for 28 days.
In a double-blind RCT of cardiovascular risk factors in healthy men, 2,000 mg of L-arginine daily was administered for 45 days.
In a blood pressure trial under traffic-related air pollution exposure, 9 g/day of L-arginine was administered for 2 weeks.
In an early fibromyalgia pilot study using malic acid combined with magnesium, the dose was 200 mg of malic acid plus 50 mg of magnesium.
In an open-label fibromyalgia treatment trial, dosages of 1,200–2,400 mg of malate and 300–600 mg of magnesium were administered for an average of 8 weeks.
In a dose-response meta-analysis of blood pressure trials, the effective dosage of L-arginine for systolic blood pressure reduction was identified as ≥4 g/day, independent of trial duration.

8. Safety Considerations and Drug Interactions

Gastrointestinal Effects

Oral supplements of arginine and citrulline increase local nitric oxide production in the small intestine, and this may be harmful under certain circumstances. Gastrointestinal toxicity has been reviewed with respect to the intestinal physiology of arginine, citrulline, ornithine, and cystine, which shares the same transporter.

L-arginine (but not lysine, ornithine, or D-arginine) induces water and electrolyte secretion mediated by NO, which acts as an absorbagogue at low levels and as a secretagogue at high levels. The action of many laxatives is NO-mediated, and there are reports of diarrhea following oral administration of arginine or ornithine.

Single doses of 3–6 g rarely provoked side effects, and healthy athletes appeared to be more susceptible than diabetic patients to gastrointestinal symptoms at individual doses >9 g. Most side effects of arginine occurred at single doses of >9 g in adults (>140 mg/kg), often when part of a daily regimen of approximately >30 g/day.

Adverse effects seemed dependent on the dosage regimen and disappeared when divided doses were ingested.

Clinical Trial Safety Data

In the vasculogenic erectile dysfunction trial using 6 g/day of L-arginine for 3 months, 5.88% of patients experienced adverse events, including gastric pyrosis, urticarial reaction, and scrotal itching, none of which was clinically relevant.

In three randomized controlled trials of malic acid for rheumatic conditions, all trials showed improvements in clinical pictures. No side effects were identified.

Interactions with Antihypertensive Agents and Nitrates

Because L-arginine supplementation may reduce blood pressure through NO-mediated vasodilation, additive hypotensive effects are theoretically possible when arginine is combined with antihypertensive medications, phosphodiesterase-5 (PDE5) inhibitors (such as sildenafil), or organic nitrates. L-arginine can modestly lower blood pressure and may interact with nitrates and PDE5 inhibitors. This interaction is of particular clinical relevance in patients who are already receiving pharmacological blood-pressure management.

Post-Myocardial Infarction Caution

A notable safety signal emerged from a clinical trial of L-arginine supplementation after acute myocardial infarction (the VINTAGE MI trial), published in JAMA in 2006, which reported unexpectedly higher mortality in the L-arginine group. Although this finding has not been replicated in all populations, it has led to caution regarding supplementation of L-arginine in patients in the post-acute myocardial infarction period. This safety signal pertains to the arginine moiety rather than to the malate salt per se, and it underscores the importance of distinguishing between patient populations in evaluating safety.

Arginine and Herpes Simplex Virus

Arginine is known to promote the replication of herpes simplex virus (HSV), as the virus requires arginine for replication, while the amino acid lysine (which competes with arginine for the same transporter) is considered inhibitory. Individuals with recurrent HSV infections are therefore generally advised to exercise caution with high-dose arginine supplementation. This consideration applies to the arginine moiety within arginine malate.

Electrolyte and Renal Considerations

Arginine hydrochloride (a closely related salt form) contains 4.8 mEq Cl⁻/g and may provoke a hyperchloremic acidosis if taken acutely in excess. This concern is specific to the hydrochloride form and is substantially reduced or absent with the malate salt, as malate is a naturally metabolized organic anion.

Training Status and Differential Response

The ergogenic response of L-citrulline or L-arginine supplements depends on the training status of the subjects. Studies involving untrained or moderately healthy subjects showed that NO donors could improve tolerance to aerobic and anaerobic exercise. However, when highly trained subjects were supplemented, no positive effect on performance was indicated. This differential response has implications for how the supplement is evaluated and for whom it may be most relevant.

9. Limitations of the Current Evidence Base

Several important limitations constrain conclusions about arginine malate specifically:

The vast majority of human clinical research has been conducted with L-arginine free base or other salt forms (notably the hydrochloride, alpha-ketoglutarate, and aspartate salts). Arginine malate as a specific formulation has not been the subject of large, well-powered, independent randomized controlled trials.
It is not established whether the malate counter-ion provides clinically meaningful additive or synergistic effects relative to L-arginine alone when taken orally in supplement doses, although the biological rationale is plausible given malate's role as a Krebs cycle intermediate.
Further testing is warranted in various populations that may benefit from nutritional supplements, including aerobic and anaerobic athletes, resistance-trained individuals, elderly people, and clinical populations, to determine the impact of different doses, timing of ingestion, and long-term and acute effects on cardiovascular health and athletic performance.
Many exercise studies show inconsistent results depending on population, training status, outcome measure, and co-supplementation. Clinical trials have shown relatively more favorable outcomes than not after supplementing with L-citrulline and combined L-arginine and L-citrulline. However, in most studies, other active ingredients such as malate were included in the supplement, making it difficult to isolate the independent contribution of the malate component.

References

Health Conditions

Health conditions that Arginine malate may help support.

Nitric OxideScientific
Arginine malate combines L-arginine with malic acid; malate supports the argininosuccinate-mediated arginine regeneration pathway and L-arginine is the direct eNOS substrate. Preclinical data show malate elevates L-arginine levels and NO production in hypertension models, giving the compound both direct substrate and metabolic recycling support for NO synthesis.

Body Systems

Body systems that Arginine malate may help support.

No body systems available.